NCT06850740

Efficacy of Co-Spinal Ondansetron In Inguinal Herniorrhaphy

The Efficacy of Co-Spinal Ondansetron In Inguinal Herniorrhaphy: A Randomized Controlled Trial

• Status: Enrolling By Invitation
• Phase: N/A
• Study type: Interventional
• Enrollment: 46 (estimated)
• Sponsor: Suez Canal University · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Ondansetron, a selective serotonin 5-HT3 receptor antagonist, is well known for its antiemetic effects. However, its ability to reduce hypotension during spinal anesthesia has recently sparked great interest. In clinical practice, administering ondansetron before spinal anesthesia has produced promising results.

Detailed description

This prospective randomized double-blinded controlled study will be conducted on 46 patients undergoing inguinal herniorrhaphy at Suez Canal University Hospital and will be randomly assigned to one of the two groups using a table of random numbers. Group A (23 patients) will be administered 8 mg of ondansetron diluted in 100 ml of normal saline, starting with the skin preparation for spinal anesthesia through the intravenous axis to be finished in 10 minutes. Group B (23 patients) will be administered 100 ml of normal saline, starting with the skin preparation for spinal anesthesia through the intravenous axis, to be finished in 10 minutes.

Conditions

• Hernia, Inguinal

Interventions

Type	Name	Description
DRUG	Ondansetron 8mg	Patients will receive 8 mg of ondansetron (ZOFATRONE®, 8 mg/4 mL, EVA Pharma, Egypt)
DRUG	Normal Saline	Patients will be managed by administering 100 ml of normal saline solution as placebo

Timeline

• Start date: 2025-03-15
• Primary completion: 2025-06-15
• Completion: 2025-08-15
• First posted: 2025-02-27
• Last updated: 2025-04-30

Locations

1 site across 1 country: Egypt